Benjamin Ebert is an associate member of the Broad Institute who participates in a Klarman Cell Observatory collaborative project that focuses on leukemia stem cells. Ebert is also an associate professor of medicine at Harvard Medical School and co-director of the Cancer Program at the Harvard Stem Cell Institute. Using a range of genomic technologies as well as classical cellular and molecular biology approaches, Ebert and his colleagues investigate the biology of specific human diseases, particularly hematopoietic malignancies and disorders of red blood cell production.
A major focus of Ebert’s laboratory is myelodysplastic syndrome (MDS), a pre-malignant disorder of hematopoietic stem cells that progresses to acute leukemia. In recent work, Ebert and his colleagues identified a gene that plays a central role in the changes that lead to 5q- syndrome, a subtype of MDS. Their findings revealed a molecular link between 5q- syndrome and congenital bone marrow failure syndromes such as Diamond-Blackfan anemia.
Ebert’s team is also actively involved in the identification and development of small molecules that could be useful for the treatment of cancer and hematologic disorders. They are studying compounds that induce fetal hemoglobin and could be useful for understanding sickle-cell anemia. In addition, Ebert and his colleagues are working on the identification and characterization of compounds that alter hematopoietic differentiation that could be useful for the treatment of cancer and non-malignant hematopoietic disorders.
Ebert received a bachelor's degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute before pursuing postdoctoral research at the Broad Institute.